Polycythemia vera (PV) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells and is caused in the vast majority of cases by activating mutations in JAK2. PV significantly increases the risk of thrombosis, cardiovascular complications, and reduced quality of life, and many patients remain dependent on regular phlebotomy to control hematocrit levels. Over time, patients may progress to myelofibrosis or acute myeloid leukemia, conditions associated with substantial morbidity and mortality.
Epetraborole, an oral, small-molecule therapy, offers a novel mechanism in PV by targeting globin synthesis. Prior clinical data in non-PV patients indicate potential for dose-dependent, reversible hematocrit reductions without broadly suppressing white cells or platelets—a profile consistent with red-cell selectivity rather than generalized cytoreduction—and without the iron deficiency seen with phlebotomy.
